Segarino, Irejane L.
HRN: 21-48-50 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/06/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/06/2022
06/12/2022
IV
500mg
Q8
PID
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominalReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes